Drospirinone: new generation of progestogen
Drospirinone is a new generation of progestogen that possesses antimineralocorticoid effect. Progestogen of this type has been used as a component in combined contraceptives. The combined contraceptives of old generation contained progestogen component of testosterone derivative. Progestogen of this type does not have antimineralcorticoid effect, such that it could cause fluid retention. As a result, women who used combined pills of this type often complained of headache, breast pain, calf pain, increased body weight and blood pressure. Owing to its androgenic effect, combined contraception pills that contained testosterone-derived progestogen may cause acne and oily face. Combined contraception that contains drospirinone does not cause headache, breast pain, calf pain, increased body weight and blood pressure. Drospirinone has such a strong anti-androgenic nature that it does not result in acne and oily face. In addition, combination of ethinylestradiol and drospirinone can be used for treating pre-menstrual syndrome and menstrual pain. Drospirinone does not affect lipid and carbohydrate metabolism. (Med J Indones 2005; 14: 190-3)
Copyright (c) 2005 Ali Baziad
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with Medical Journal of Indonesia agree to the following terms:
- Authors retain copyright and grant Medical Journal of Indonesia right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial License that allows others to remix, adapt, build upon the work non-commercially with an acknowledgment of the work’s authorship and initial publication in Medical Journal of Indonesia.
- Authors are permitted to copy and redistribute the journal's published version of the work non-commercially (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Medical Journal of Indonesia.